Gut Microbiome-Liver-Brain axis in Alcohol Use Disorder. The role of gut dysbiosis and stress in alcohol-related cognitive impairment progression: possible therapeutic approaches.
Neurobiology of Stress,
Год журнала:
2025,
Номер
35, С. 100713 - 100713
Опубликована: Фев. 8, 2025
The
Gut
Microbiome-Liver-Brain
Axis
is
a
relatively
novel
construct
with
promising
potential
to
enhance
our
understanding
of
Alcohol
Use
Disorder
(AUD),
and
its
therapeutic
approaches.
Significant
alterations
in
the
gut
microbiome
occur
AUD
even
before
any
other
systemic
signs
or
symptoms
manifest.
Prolonged
inappropriate
alcohol
consumption,
by
affecting
microbiota
mucosa
permeability,
thought
contribute
development
behavioral
cognitive
impairments,
leading
Alcohol-Related
Liver
Disorders
potentially
progressing
into
alcoholic
cirrhosis,
which
often
associated
severe
impairment
related
neurodegeneration,
such
as
hepatic
encephalopathy
dementia.
critical
role
further
supported
efficacy
FDA-approved
treatments
for
cirrhosis
(i.e.,
lactulose
rifaximin).
To
stimulate
new
research,
we
hypothesize
that
interactions
between
maladaptive
stress
response
constitutional
predisposition
neurodegeneration
underlie
progression
conditions
Clinical
Concerns
impairment,
represent
significant
costly
burden
society.
Early
identification
individuals
at
risk
developing
these
could
help
prioritize
integrated
interventions
targeting
different
substrates
axis.
Specifically,
addiction
medications,
modulators,
stress-reducing
interventions,
and,
possibly
soon,
agents
reduce
steatosis/fibrosis
will
be
discussed
context
digitally
explicit
goal
this
treatment
performed
on
early
stage
disorder
would
transition
from
those
Common
strategy
recommended
most
neurological
neurodegenerative
disorders.
Язык: Английский
Recognition, management, and patient perspectives of impulsive-compulsive disorders in Parkinson’s disease
Journal of Parkinson s Disease,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 16, 2025
Background
Impulsive-compulsive
disorders
(ICDs)
are
commonly
acknowledged
as
side
effects
of
dopaminergic
therapy
in
Parkinson’s
disease
(PD).
While
many
large-scale
studies
have
focused
on
prevalences
and
high-risk
treatments,
little
is
known
about
practical
management
ICDs
clinical
care
patients’
experiences.
Objective
To
investigate
how
recognized
PD
care,
features
patients
with
ICDs,
impacted
by
their
ICD.
Methods
Questionnaires
were
sent
to
all
who
reported
ICD
symptoms
the
Swedish
quality
register
for
Skåne
County
(n
=
170)
medical
records
screened
mention
ICDs.
Core
subjects
communication
between
clinician
patient,
course
impact
different
life
domains.
Results
Despite
sufficient
awareness
risk
during
treatment,
there
was
limited
staff
regarding
Only
49%
had
part
only
14%
been
asked
it.
Additionally,
collaboration
psychiatry
rare
(12%).
severity
increased
over
time
ongoing
most
a
mild
moderate
close
relationships,
family,
mental
physical
health.
Conclusions
This
study
identified
insufficient
very
involvement
health
services.
Thus,
improve
prevention
should
be
recognized,
monitored
treated
more
systematically
routine
services
increased.
Язык: Английский
Acetaldehyde-driven mRNA methylation and expression changes in ethanol-metabolizing enzyme genes
Epigenetics,
Год журнала:
2025,
Номер
20(1)
Опубликована: Апрель 19, 2025
This
study
examines
how
the
alcohol
metabolite
acetaldehyde
modulates
mRNA
methylation
and
expression
of
ethanol-metabolizing
genes,
uncovering
its
epigenetic
role
in
ethanol
metabolism.
Using
neuron-like
(SH-SY5Y)
non-neuronal
(SW620)
cellular
models,
we
examined
effects
chronic
intermittent
(CIA)
exposure
subsequent
withdrawal
(CIA+WD)
on
global
RNA
m6A
modifications
three
brain
genes:
CAT
(catalase),
CYP2E1
(cytochrome
P450
2E1),
ALDH2
(aldehyde
dehydrogenase
2).
A
3-week
CIA
exposure,
with
or
without
24-hour
withdrawal,
did
not
significantly
alter
levels
either
cell
line.
However,
exposure/withdrawal
induced
hypermethylation
at
stop
codon
regions
(CIA:
p
=
0.002;
CIA+WD:
0.055)
0.077;
0.036)
SH-SY5Y
cells,
but
SW620
cells.
Furthermore,
was
upregulated
both
types
following
(SH-SY5Y:
0.073
[CIA]
0.00002
[CIA+WD];
SW620:
0.0009
0.00008
[CIA+WD]).
In
contrast,
remained
unchanged.
These
findings
highlight
cell-specific
acetaldehyde,
particularly
modulating
ALDH2,
a
key
enzyme
Язык: Английский
Alcohol Use Disorder Associated GeneFNDC4Alters Glutamatergic and GABAergic Neurogenesis
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2025,
Номер
unknown
Опубликована: Май 16, 2025
Large-cohort
genome-wide
association
studies
(GWAS)
for
alcohol
use
disorder
(AUD)
and
AUD-related
phenotypes
have
identified
more
than
one
hundred
genetic
loci.
Functional
study
of
those
GWAS-identified
loci
might
represent
an
important
step
toward
understanding
AUD
pathophysiology.
We
found
that
which
are
splicing
quantitative
trait
(sQTLs)
the
fibronectin
III
domain
containing
4
(
FNDC4
)
gene
in
brain
were
by
GWAS
both
drug
treatment
outcomes
risk.
However,
function
how
it
contribute
to
pathophysiology
remain
unknown.
In
present
study,
we
characterized
locus-associated
splice
isoforms,
suggested
alternative
results
loss-of-function
FNDC4.
also
investigated
using
CRISPR/cas9
editing,
creation
human
induced
pluripotent
stem
cell
(iPSC)-derived
neural
organoids
joined
with
single-nucleus
RNA
sequencing.
observed
knock-out
(KO)
resulted
a
striking
shift
relative
proportions
glutamatergic
GABAergic
neurons
iPSC-derived
organoids,
suggesting
possible
role
neurogenesis.
explored
potential
mechanism(s)
-dependent
neurogenesis
mediating
cell-cell
interaction.
summary,
this
series
experiments
indicates
plays
regulating
cerebral
cortical
brain.
This
regulation
may
response
pharmacotherapy
as
well
effects
on
Язык: Английский